Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alpha Emitters: Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.

The global market for Alpha Emitters estimated at US$684.5 Million in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 20.6% over the analysis period 2020-2027.

Bone Metastasis, one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$888.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 21.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $203.1 Million, While China is Forecast to Grow at 19.9% CAGR

The Alpha Emitters market in the U.S. is estimated at US$203.1 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$437.5 Million by the year 2027 trailing a CAGR of 19.9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.4% and 17.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Pancreatic Cancer Segment to Record 21.2% CAGR

In the global Pancreatic Cancer segment, USA, Canada, Japan, China and Europe will drive the 21.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$94.5 Million in the year 2020 will reach a projected size of US$357.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 12 Featured) –

Actinium Pharmaceuticals, Inc.

Alpha Tau Medical

Bayer AG

Fusion Pharma

IBA Group

IBA Radiopharma Solutions

Lantheus Medical Imaging, Inc.

NTP Radiosotopes SOC Ltd.

RadioMedix, Inc.

Siemens Healthineers

Telix Pharmaceuticals Ltd.

Triad Isotopes, Inc.

What’s New for 2022?

Global competitiveness and key competitor percentage market shares

Market presence across multiple geographies – Strong/Active/Niche/Trivial

Online interactive peer-to-peer collaborative bespoke updates

Access to digital archives and a Research Platform

Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Alpha Emitters – Global Key Competitors Percentage Market Share in 2022 (E)

Impact of Covid-19 and a Looming Global Recession

Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/sjgsx1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.